SS Innovations SEC Filings

SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported a bona fide gift of 1,000,000 shares of common stock held indirectly through Sushruta Pvt. Ltd. The transaction carried a price of $0.00 per share. After the gift, 108,564,261 shares are reported as indirectly owned through Sushruta Pvt. Ltd., reflecting a large remaining position.

SS Innovations International, Inc. reported a major technical milestone: a robot-assisted heart procedure using its SSi Mantra surgical robotic system was successfully performed across approximately 12,500 miles (20,000 kilometers) of fiber network distance between Guyana and India, described as the world’s longest-distance robotic telesurgery.

The procedure used the optional SSi MantrAsana tele-surgeon console, operated remotely by CEO and cardiac surgeon Dr. Sudhir Srivastava, with the patient-side setup in Indore, India and network latency of 290-300 milliseconds. To date, 22 cardiac telesurgeries and 173 total telesurgeries have been completed using SSi Mantra, which the company states is the only system globally used for robotic cardiac telesurgery.

SSi Mantra has regulatory approval in 14 countries, including India, Guyana, Colombia, Kenya, and the United Arab Emirates, and has been clinically validated in India in more than 170 different types of surgical procedures. The company positions its platform as a modular, multi-arm, 3D 4K-capable robotic system designed to make robotic surgery more affordable and widely accessible.

SS Innovations International, Inc. insider Barry F. Cohen, who serves as COO - Americas and a director, reported a bona fide gift of 25,000 shares of Common Stock. The transaction carried a stated price of $0.00 per share. After the gift, he directly holds 7,755,088 shares.

SS Innovations International, Inc. reported a senior leadership change. On May 18, 2026, Milan Rao informed the company he will step down as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026.

The company stated that it has begun a search process to identify and recruit a permanent successor for the Chief Financial Officer role. No additional details about interim arrangements or reasons for the departure are provided in this report.

SS Innovations International, Inc. files a shelf prospectus to register up to $150,000,000 of securities and to permit resale of up to 5,016,500 shares of common stock by selling shareholders.

The prospectus registers multiple securities types (common stock, preferred, warrants, rights, units, debt) and specifically covers 5,016,500 Shares comprised of shares sold in a March 6, 2026 private placement, and shares issuable upon exercise of RCP Warrants (41,667 shares, $3.45 exercise) and HCW Warrants (500,000 shares, $8.89 exercise). The company will receive proceeds only if those warrants are exercised.

The filing describes the SSi Mantra surgical robotic system, regulatory filings including a 510(k) submission to the FDA, an installed base of 194 systems as of March 31, 2026, and cumulative use in 9,744 procedures. The prospectus discloses concentrated control by Dr. Sudhir Srivastava (approx. 55.84% beneficial ownership) and material risk factors including continued losses, regulatory and manufacturing risks, and the need for additional financing.

SS Innovations International, Inc. insider reporting shows an "other" type transaction involving indirect holdings associated with Chairman and CEO Sudhir Srivastava. An entity he controls, Sushruta Pvt. Ltd., transferred 21,506 shares of common stock at $5.0000 per share.

The transfer was made pursuant to a settlement agreement dated May 4, 2026. After this restructuring, Sushruta Pvt. Ltd. is reported as holding 109,564,261 shares of SS Innovations common stock indirectly for Srivastava, indicating the transaction is very small relative to his overall position.

SS Innovations International, Inc. reported record unaudited first quarter 2026 revenue of $11.1 million, up about 117% from $5.1 million a year earlier, driven mainly by higher SSi Mantra system and instrument sales. System sales rose to $9.6 million and instruments to $1.2 million, while total revenue increased 116.8%.

Gross profit expanded to $5.3 million from $1.1 million. The company still posted a net loss of $3.6 million, but this improved from a $5.7 million loss in the prior-year quarter as operating loss narrowed. Installations of the SSi Mantra system grew to 26 in the quarter, with a cumulative installed base of 194 systems and 1,859 surgeries performed.

Liquidity strengthened significantly. Cash flows from financing activities included $18.6 million in gross proceeds from a March 2026 private placement, contributing to cash and cash equivalents of $24.0 million at March 31, 2026. Management highlighted ongoing regulatory efforts, including U.S. FDA review of a 510(k) submission and progress toward European Union CE marking for the SSi Mantra.

SS Innovations International, Inc. reported strong top-line growth but continued losses for the three months ended March 31, 2026. Revenue rose to $11,101,366 from $5,120,610 a year earlier, driven mainly by higher system sales.

The company posted a net loss of $3,582,571, improving from a $5,681,353 loss, with results heavily affected by non-cash stock compensation of $3,144,315 and depreciation of $323,747. Cash, cash equivalents and restricted cash increased to $24,005,680, helped by a private placement that generated net proceeds of $18,446,498.

Despite a working capital surplus of $40,216,514, management disclosed that recurring losses, dependence on related-party funding, and insufficient projected cash flows raise substantial doubt about the company’s ability to continue as a going concern over the next 12 months, absent additional financing and successful execution of growth plans.